These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 20054641)

  • 1. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
    Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
    Masri S; Phung S; Wang X; Chen S
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
    Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
    BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
    J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
    Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
    Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
    Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
    Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
    Wong C; Wang X; Smith D; Reddy K; Chen S
    Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
    Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
    Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
    Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
    J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
    Gilani RA; Kazi AA; Shah P; Schech AJ; Chumsri S; Sabnis G; Jaiswal AK; Brodie AH
    Breast Cancer Res Treat; 2012 Oct; 135(3):681-92. PubMed ID: 22878889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
    Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
    Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
    Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
    Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
    Chen HY; Liu ZH
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
    Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
    Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.